# FDA recall D-1613-2014

> **Eugene Oregon, Inc.** · Class I · drug recall initiated 2014-05-05.

## Product

Black Ant, 2800 mg, four capsules per box, Manufacturer Qinghai Baojiantang Pharmaceutical Co., Ltd.

## Reason for recall

Marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sildenafil.

## Distribution

To retailers in MD, TX, FL, PA, IL, NJ, IN, LA, WA, ME, SC

## Key facts

- **Recall number:** D-1613-2014
- **Recalling firm:** Eugene Oregon, Inc.
- **Classification:** Class I
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2014-05-05
- **Report date:** 2014-10-08
- **Termination date:** 2015-04-01

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Levittown, PA, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1613-2014

## Citation

> AI Analytics. FDA recall D-1613-2014. Retrieved 2026-06-23 from https://api.ai-analytics.org/recall/D-1613-2014. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*